Advertisement DEA approves Pharmatek to analyze controlled substances - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

DEA approves Pharmatek to analyze controlled substances

The US Drug Enforcement Agency (DEA) has approved Pharmatek Laboratories to perform analytical and stability testing for all controlled-substance drug products within its both non-potent and potent GMP facilities.

Controlled substances are designated as Schedule I-V according to their medical use, potential for abuse and safety or dependence liability.

Pharmatek CEO and CSO Jeffrey Bibbs said the receipt of the additional registration from the DEA demonstrates that they meet the agency’s stringent requirements, and further validates their facility design, security systems, and procedures for analysis, handling, storage and disposal of controlled substances.